HistoSonics August 2024 Series D Funding round

HistoSonics, a medical device company developing non-invasive platforms using histotripsy technology, announced it secured $102 million in Series D funding led by Alpha Wave Ventures. The round included new investors Amzak Health and HealthQuest Capital, as well as existing backers like Johnson & Johnson Innovation - JJDC Inc., Lumira Ventures, and others. The funding will support the commercialization of the Edison Histotripsy System, expand histotripsy applications, and initiate the BOOMBOX Master Study to evaluate liver tumor treatment. CEO Mike Blue emphasized the potential of histotripsy as a non-invasive tumor treatment option.